Prostate cancer patients in a trial of Novacea’s DN-101 (Asentarâ„¢) plus Taxotere showed longer median survival and fewer serious side effects compared with patients who received Taxotere alone, a study has found. The large, randomized Phase 2 trial reports today that standard chemotherapy for metastatic androgen-independent prostate cancer (AIPC) was enhanced for patients who received DN-101 (Asentarâ„¢), which is a new formulation of high-strength vitamin D. The group that received the drug before each chemotherapy session showed some increase in survival. Those given the drug also had reduction of some common side effects of the chemotherapy and of advanced prostate cancer, notably, fewer blood clots. Full Story… read on.